Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Lixte Biotechnology Holdings ( (LIXT) ).
On December 30, 2025, Lixte Biotechnology Holdings, Inc. entered into a share exchange agreement with Orbit Capital Inc. under which Orbit exchanged 2,700 shares of Lixte’s Series C preferred stock for 700,000 shares of Lixte common stock and 200 ordinary shares in Lixte’s wholly owned UK subsidiary, Liora Technologies Europe Ltd., representing 20% of Liora’s outstanding securities. Following the closing of this transaction, all of Lixte’s Series C preferred shares were cancelled and Lixte retained 800 ordinary shares of Liora, effectively simplifying its capital structure by eliminating the outstanding Series C preferred stock while partially divesting its direct ownership stake in its European subsidiary to Orbit in a privately negotiated, unregistered securities transaction.
More about Lixte Biotechnology Holdings
Lixte Biotechnology Holdings, Inc. is a Delaware-incorporated biotechnology company that operates through subsidiaries including Liora Technologies Europe Ltd., organized under the laws of England and Wales. The group structures its capital through preferred and common equity and appears focused on optimizing its corporate and subsidiary ownership interests, including international holdings such as Liora Technologies Europe.
Average Trading Volume: 100,749
Technical Sentiment Signal: Hold
Current Market Cap: $31.37M
Learn more about LIXT stock on TipRanks’ Stock Analysis page.